Document is current
Any future updates will be listed below
-
Authors
Eckenweber, Florian
Medina-Luque, Jose
Blume, Tanja
Sacher, Christian
Biechele, Gloria
Wind, Karin
Deussing, Maximilian
Briel, Nils
Lindner, Simon
Boening, Guido
von Ungern-Sternberg, Barbara
Unterrainer, Marcus
Albert, Nathalie L.
Zwergal, Andreas
Levin, Johannes
Bartenstein, Peter
Cumming, Paul
Rominger, Axel
Höglinger, Günter U.
Herms, Jochen
Brendel, Matthias http://orcid.org/0000-0002-9247-2843
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (BR4580/1-1, RO5194/1-1, EXC 2145 SyNergy – ID 390857198)
- License Information
-
More Information
Article History
Received: 16 March 2020
Accepted: 30 June 2020
First Online: 13 July 2020
Ethics approval
: All experiments were carried out in compliance with the National Guidelines for Animal Protection, Germany, with the approval of the regional Animal Care Committee of the Government of Oberbayern (Regierung Oberbayern) and were overseen by a veterinarian. Animal experiments were conducted in accordance with the guidelines EU Directive 2010/63/EU for animal experiments.
: Not applicable.
: G.U.H. received research support from GE Healthcare and Neuropore; has ongoing research collaborations with Orion and Prothena; serves as a consultant for AbbVie, AlzProtect, Asceneuron, Biogen, Biohaven, Lundbeck, Novartis, Roche, Sanofi, and UCB; received honoraria for scientific presentations from AbbVie, Biogen, Roche, Teva, UCB, and Zambon; and holds a patent on PERK Activation for the Treatment of Neurodegenerative Diseases (PCT/EP2015/068734). M.B. received speaking honoraria from Life Molecular Imaging and GE healthcare. M.B. is an advisor of Life Molecular Imaging. All other authors report no conflicts of interest.
